Literature DB >> 28419994

Degradation of Mcl-1 through GSK-3β Activation Regulates Apoptosis Induced by Bufalin in Non-Small Cell Lung Cancer H1975 Cells.

Xiao-Hong Kang1, Jing-Hang Zhang2, Qing-Qin Zhang1, Yan-Hui Cui1, Ying Wang1, Wei-Zheng Kou1, Zhan-Hui Miao1, Ping Lu1, Li-Fang Wang3, Zhen-Ye Xu3, Fei Cao4.   

Abstract

BACKGROUND/AIMS: Mcl-1, an anti-apoptotic Bcl-2 family member, is often overexpressed in non-small cell lung cancer (NSCLC). Bufalin has been reported to induce apoptosis in various tumor cells. However, there is no report showing that bufalin could downregulate Mcl-1 expression in NSCLC.
METHODS: Cell proliferation was analyzed by cell counting kit-8 (CCK-8) assay in H1975 cells. Cell apoptosis was detected by flow cytometry. Mcl-1 mRNA was detected by RT-PCR. The expression of apoptosis-associated proteins in H1975 cells was detected by western blotting. The levels of Mcl-1 ubiquitination and NOXA were analyzed by Immunoprecipitation assay.
RESULTS: Cell growth was inhibited by bufalin in a time and dose-dependent manner. Bufalin induced apoptosis in NSCLC cells by activating caspase cascades and downregulating Mcl-1 expression. However, overexpression of Mcl-1 diminished bufalin-induced apoptosis. Furthermore, bufalin did not reduce Mcl-1 mRNA expression in H1975 cells, but strongly promoted Mcl-1 protein degradation. Proteasome inhibitor MG132 markedly prevented the degradation of Mcl-1 and blocked bufalin-induced Mcl-1 reduction. Bufalin did not significantly affect NOXA protein levels, but downregulated the expression of p-GSK-3β. GSK-3 inhibitor and GSK-3β siRNA resulted in increased levels of Mcl-1 and reversed the bufalin-induced Mcl-1 degradation.
CONCLUSION: Bufalin induced cell apoptosis in H1975 cells may be through downregulation of Mcl-1. Proteasomal degradation of Mcl-1 via GSK-3β activation was involved in bufalin-induced apoptosis.
© 2017 The Author(s)Published by S. Karger AG, Basel.

Entities:  

Keywords:  Apoptosis; Bufalin; Glycogen synthase kinase-3β; Mcl-1; NSCLC

Mesh:

Substances:

Year:  2017        PMID: 28419994     DOI: 10.1159/000475438

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  16 in total

1.  Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer.

Authors:  Dongxing Ji; Zhiyong Liang; Guixin Liu; Guangzong Zhao; Jun Fang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-08-24       Impact factor: 3.000

2.  Combination Treatment of Sorafenib and Bufalin Induces Apoptosis in NCI-H292 Human Lung Cancer Cells In Vitro.

Authors:  Shu-Fen Peng; Jing-Gung Chung; Jung-Yu Kuo; Ching-Lung Liao; Yi-Shih Ma; Chao-Lin Kuo; Jaw-Chyun Chen; Yi-Ping Huang; Wen-Wen Huang
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

3.  Delayed neutrophil apoptosis may enhance NET formation in ARDS.

Authors:  Chao Song; Haitao Li; Zhi Mao; Ling Peng; Ben Liu; Fengyu Lin; Yi Li; Minhui Dai; Yanhui Cui; Yuhao Zhao; Duoduo Han; Lingli Chen; Xun Huang; Pinhua Pan
Journal:  Respir Res       Date:  2022-06-13

4.  Effect of Bufalin-PLGA Microspheres in the Alleviation of Neuropathic Pain via the CCI Model.

Authors:  Lina Long; Wenwei Zhong; Liwei Guo; Jing Ji; Hong Nie
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

5.  Modulatory effects of bufalin, an active ingredient from toad venom on voltage-gated sodium channels.

Authors:  Jie Tao; Feng Jiang; Cheng Liu; Zhirui Liu; Yudan Zhu; Jian Xu; Yiqin Ge; Kan Xu; Peihao Yin
Journal:  Mol Biol Rep       Date:  2018-06-21       Impact factor: 2.316

Review 6.  MCL-1 inhibition in cancer treatment.

Authors:  Weiguo Xiang; Chao-Yie Yang; Longchuan Bai
Journal:  Onco Targets Ther       Date:  2018-10-23       Impact factor: 4.147

7.  Transferrin and folic acid co-modified bufalin-loaded nanoliposomes: preparation, characterization, and application in anticancer activity.

Authors:  Qiankun Chen; Ji Liu
Journal:  Int J Nanomedicine       Date:  2018-10-05

8.  Telocinobufagin and Marinobufagin Produce Different Effects in LLC-PK1 Cells: A Case of Functional Selectivity of Bufadienolides.

Authors:  Luciana S Amaral; Jainne Martins Ferreira; Danilo Predes; José Garcia Abreu; François Noël; Luis Eduardo M Quintas
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

Review 9.  Anticancer and Immunogenic Properties of Cardiac Glycosides.

Authors:  Naira Fernanda Zanchett Schneider; Claudia Cerella; Cláudia Maria Oliveira Simões; Marc Diederich
Journal:  Molecules       Date:  2017-11-08       Impact factor: 4.411

10.  Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma.

Authors:  Raphael Berges; Emilie Denicolai; Aurélie Tchoghandjian; Nathalie Baeza-Kallee; Stephane Honore; Dominique Figarella-Branger; Diane Braguer
Journal:  Cell Death Dis       Date:  2018-09-24       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.